Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Prothrombin complex concentrate is manufactured through a process of ion-exchange chromatography from the cryoprecipitate supernatant of large plasma pools after the removal of factor XI and antithrombin. These concentrates are used to treat and prevent bleeding in the case of hemophilia B if a pure factor IX is not present.

An emerging factor driving the prothrombin complex concentrate market growth is rising prevalence of hemophilia B

For instance, according to the Centers for Disease Control and Prevention (CDC) report, Hemophilia A occurs in 1 out of 5,000 live male births. It is around four times more common than Hemophilia B. Few effective treatments available for hemophilia require lifetime infusion of expensive drugs manufactured through recombinant biotechnology or from human plasma.

The global prothrombin complex concentrates market is estimated to be valued at US$ 771.2 million in 2021 and is expected to exhibit a CAGR of 10.2%  over the forecast period (2021-2028).

Figure 1. Global Prothrombin Complex Concentrates Market Share (%) in Terms of Value, By Region, 2021

Prothrombin Complex Concentrates  | Coherent Market Insights

Increasing approval of product by regulatory bodies is expected to increase the growth of the global prothrombin complex concentrates market over the forecast period.

For instance, in 2013, CSL Behring has received the U.S. Food and Drug Administration (FDA) approval for Kcentra (Prothrombin Complex Concentrate) for the indication of  urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients needing an urgent surgery or other invasive procedure.

request-sample

Prothrombin Complex Concentrates Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 771.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 10.2% 2028 Value Projection: US$ 1,522.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: 3-Factor PCC, 4-Factor PCC
  • By Application: Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency, Others
  • By End User: Hospital, Ambulatory Surgical Centres, Others
Companies covered:

Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin

Growth Drivers:
  • Increasing approval of product by regulatory bodies
  • Increasing prevalence of hemophilia B
Restraints & Challenges:
  • Thrombotic complication related to PCC

Figure 2. Global Prothrombin Complex Concentrates Market Share (%), by Type, 2021

Prothrombin Complex Concentrates  | Coherent Market Insights

Global Prothrombin Complex Concentrates Market Restraint

The major factors that hinder the growth of the prothrombin complex concentrates market include thrombotic complication resulting from the use of prothrombin complex concentrates  such as venous thromboembolism, micro vascular thrombosis, and myocardial infraction.

Key Players

Major players operating in the global prothrombin complex concentrates market include Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin

Prothrombin complex concentrates (PCCs) are highly purified concentrate prepared from blood plasma with hemostatic activity contain four vitamin K-dependent clotting factors (F) (II (prothrombin), VII, IX and X), for replacement therapy in patients with congenital or acquired deficiencies.

Moreover, in several European countries, prothrombin complex concentrates are also used in the management of massive peri- and postoperative bleeding.

Market Dynamics

Global Prothrombin Complex Concentrates Market is expected to show significant growth, owing to increasing approval of product. For instance, in 2013, the U.S Food and Drug Administration (FDA) accepted Octapharma USA’s Biological License Application (BLA) for octaplex 4-Factor PCC, for indication of reversal of anticoagulation therapy in patients undergoing vitamin K antagonist therapy with the need for urgent surgery or invasive procedures

Key features of the study:

  • This report provides in-depth analysis of the global prothrombin complex concentrates market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global prothrombin complex concentrates market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Octapharma AG, Nihon Pharmaceutical Co Ltd, Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global prothrombin complex concentrates market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prothrombin complex concentrates market

Detailed Segmentation:

  • Global Prothrombin Complex Concentrates Market, By Type:
    • 3-Factor PCC
    • 4-Factor PCC
  • Global Prothrombin Complex Concentrates Market, By Application:
    • Acquired Coagulation Factor Deficiency
    • Congenital Coagulation Factor Deficiency
    • Others
  • Global Prothrombin Complex Concentrates Market, By End User:
    • Hospital
    • Ambulatory Surgical Centres
    • Others
  • Global Prothrombin Complex Concentrates Market, By Region:
    • North America
      • By Type
        • 3-Factor PCC
        • 4-Factor PCC
      • By Application
        • Acquired Coagulation Factor Deficiency
        • Congenital Coagulation Factor Deficiency
        • Others
      • By End User
        • Hospital
        • Ambulatory Surgical Centres
        • Others
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Type
        • 3-Factor PCC
        • 4-Factor PCC
      • By Application
        • Acquired Coagulation Factor Deficiency
        • Congenital Coagulation Factor Deficiency
        • Others
      • By End User
        • Hospital
        • Ambulatory Surgical Centres
        • Others
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type
        • 3-Factor PCC
        • 4-Factor PCC
      • By Application
        • Acquired Coagulation Factor Deficiency
        • Congenital Coagulation Factor Deficiency
        • Others
      • By End User
        • Hospital
        • Ambulatory Surgical Centres
        • Others
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type
        • 3-Factor PCC
        • 4-Factor PCC
      • By Application
        • Acquired Coagulation Factor Deficiency
        • Congenital Coagulation Factor Deficiency
        • Others
      • By End User
        • Hospital
        • Ambulatory Surgical Centres
        • Others
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type
        • 3-Factor PCC
        • 4-Factor PCC
      • By Application
        • Acquired Coagulation Factor Deficiency
        • Congenital Coagulation Factor Deficiency
        • Others
      • By End User
        • Hospital
        • Ambulatory Surgical Centres
        • Others
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type
        • 3-Factor PCC
        • 4-Factor PCC
      • By Application
        • Acquired Coagulation Factor Deficiency
        • Congenital Coagulation Factor Deficiency
        • Others
      • By End User
        • Hospital
        • Ambulatory Surgical Centres
        • Others
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Octapharma AG*
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Nihon Pharmaceutical Co Ltd
    • Grifols S.A.
    • CSL Behring GmbH
    • Kedrion Biopharma Inc.
    • Shire Plc
    • China Biologic Products Holdings, Inc.
    • Sanquin

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Application
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Epidemiology
    • Mergers and Acquisitions
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Pipeline Analysis
    • Research and development
  4. Global Prothrombin Complex Concentrates Market – Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Supply and Demand Analysis
  5. Global Prothrombin Complex Concentrates Market, By Type, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • 3-Factor PCC
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • 4-Factor PCC
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  6. Global Prothrombin Complex Concentrates Market, By Application, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Acquired Coagulation Factor Deficiency
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Congenital Coagulation Factor Deficiency
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  7. Global Prothrombin Complex Concentrates Market, By End User, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Ambulatory Surgical Centres
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  8. Global Prothrombin Complex Concentrates Market, By Region, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2028
    • North America
      • Market Size and Forecast, By Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By End User, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By End User, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By End User, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By End User, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By End User, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By End User, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Competitive Snapshot
      • Octapharma AG*
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Nihon Pharmaceutical Co Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Grifols S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CSL Behring GmbH
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Kedrion Biopharma Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Shire Plc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • China Biologic Products Holdings, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanquin
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 30 figures on "Prothrombin Complex Concentrates Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global prothrombin complex concentrates market size is estimated to be valued at US$ 771.2 million in 2021 and is expected to exhibit a CAGR of 10.2% between 2021 and 2028.
Increasing approval of products and increasing prevalence of hemophilia B are expected to drive the market growth over the forecast period.
North America holds the largest market share in the market.
Major factor hampering the growth of the market includes the thrombotic complication related to PCC .
Major players operating in the market include Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc. and Sanquin
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.